NCT04712539View on ClinicalTrials.gov

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
Hematopoietic and Lymphoid Cell NeoplasmInfluenza
Interventions
DRUG

Baloxavir Marboxil

Given PO

DRUG

Oseltamivir

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER